Combined: Absence of rebleeding + survival 1 year [clinicaltrials_resource:a10872774068f09eb6f39db877777eb4]
The primary endpoint combines absence of rebleeding + survival during the first 1 year after inclusion in the study. Patients to compare are those with liver cirrhosis and acute bleeding from IGV1 or GOV2 varices initially treated with combined pharmacological and endoscopic therapy. Those patients will be randomized to receive a TIPS or standard medical therapy (pharmacological + endoscopic injection of tissue adhesives)
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Combined: Absence of rebleeding + survival 1 year [clinicaltrials_resource:a10872774068f09eb6f39db877777eb4]
The primary endpoint combines absence of rebleeding + survival during the first 1 year after inclusion in the study. Patients to compare are those with liver cirrhosis and acute bleeding from IGV1 or GOV2 varices initially treated with combined pharmacological and endoscopic therapy. Those patients will be randomized to receive a TIPS or standard medical therapy (pharmacological + endoscopic injection of tissue adhesives)
Bio2RDF identifier
a10872774068f09eb6f39db877777eb4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a10872774068f09eb6f39db877777eb4
measure [clinicaltrials_vocabulary:measure]
Combined: Absence of rebleeding + survival
time frame [clinicaltrials_vocabulary:time-frame]
description
The primary endpoint combines ...... injection of tissue adhesives)
identifier
clinicaltrials_resource:a10872774068f09eb6f39db877777eb4
title
Combined: Absence of rebleeding + survival 1 year
@en
type
label
Combined: Absence of rebleedin ...... 872774068f09eb6f39db877777eb4]
@en